In Myriad, Did Supreme Court Confuse Its Own Precedent?

Law360, New York (August 5, 2013, 1:43 PM EDT) -- On June 13, 2013, the United States Supreme Court issued its long-awaited decision in Association for Molecular Pathology v. Myriad Genetics Inc., and held that isolated genes are not patent eligible subject matter under 35 U.S.C. § 101. 569 U.S. ___, slip. op. at 13, 17 (2013). To reach this conclusion, the court relied on Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948), a case in which a patent for a mixture of bacteria was held invalid because the mixture “fell short...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.